Skip to main content
Erschienen in: Medical Oncology 3/2011

01.09.2011 | Original Paper

The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast

verfasst von: Nagehan Ozdemir Barısık, Sevinc Hallac Keser, Aylin Ege Gul, Sibel Sensu, Nilufer Onak Kandemir, Hasan Fehmi Kucuk, Mahmut Gumus, Nimet Karadayı

Erschienen in: Medical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Cyclooxygenase is an enzyme that changes the immune response to malign cells and catalyzes prostaglandins that may have an impact on cell proliferation. The purpose of this study was to examine the relation between established clinicopathological parameters in breast carcinomas and COX-2 protein expression. COX-2, estrogen receptor (ER), progesterone receptor (PR) and c-erB-2 primary antibodies were assessed in the slides prepared from the paraffin blocks of 62 invasive ductal carcinoma cases. The relation between ER, PR, and c-erbB-2 positivity, histological grade, nuclear grade, lymphovascular invasion, tumor diameter, lymph node positivity, metastasis, and age were evaluated. The results were analyzed statistically. Cytoplasmic COX-2 expression was seen in 75.8% of all breast carcinomas. In both univariate and multivariate logistic regression analysis, there was a positive correlation between COX-2 expression and negative ER status, respectively (P = 0.0173) (P = 0.016). There was any statistically significant relation between PR positivity, c-erbB-2 positivity, histological grade, nuclear grade, lymphovascular invasion, tumor diameter, lymph node positivity, metastasis, and age (P ≥ 0.05). Given that there was found a statistically significant relation between COX-2 expression and negative ER status, which is considered a poor prognostic parameter, suggests that COX-2 expression can have a place among the other prognostic parameters of breast carcinoma.
Literatur
1.
Zurück zum Zitat Denkert C, Winzer KJ, Müler BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978–87.PubMedCrossRef Denkert C, Winzer KJ, Müler BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978–87.PubMedCrossRef
2.
Zurück zum Zitat Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology. 2005;46:561–8.PubMedCrossRef Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology. 2005;46:561–8.PubMedCrossRef
3.
Zurück zum Zitat Fadden DW, Riggs DR, Jackson BJ, Cunningham C. Additive effect of COX-1 and COX-2 inhibition on breast cancer in vitro. Int J Oncol. 2006;29:1019–23. Fadden DW, Riggs DR, Jackson BJ, Cunningham C. Additive effect of COX-1 and COX-2 inhibition on breast cancer in vitro. Int J Oncol. 2006;29:1019–23.
4.
Zurück zum Zitat Tan KB, Yong WP, Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of breast. Histopathology. 2004;44:24–8.PubMedCrossRef Tan KB, Yong WP, Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of breast. Histopathology. 2004;44:24–8.PubMedCrossRef
5.
Zurück zum Zitat Soslow AS, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89:2637–45.PubMedCrossRef Soslow AS, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89:2637–45.PubMedCrossRef
6.
Zurück zum Zitat Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem. 2006;281:12210–7.PubMedCrossRef Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem. 2006;281:12210–7.PubMedCrossRef
7.
Zurück zum Zitat Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106:1443–52.PubMedCrossRef Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106:1443–52.PubMedCrossRef
8.
Zurück zum Zitat Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer. 2006;94:253–8.PubMedCrossRef Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer. 2006;94:253–8.PubMedCrossRef
9.
Zurück zum Zitat Howe LR, Chang SH, Tolle KC, et al. HER-2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005;65:10113–9.PubMedCrossRef Howe LR, Chang SH, Tolle KC, et al. HER-2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005;65:10113–9.PubMedCrossRef
10.
Zurück zum Zitat Howe LR. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210.PubMedCrossRef Howe LR. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210.PubMedCrossRef
11.
Zurück zum Zitat Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology. 2005;72:241–9.PubMedCrossRef Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology. 2005;72:241–9.PubMedCrossRef
12.
Zurück zum Zitat Watson J, Chuah SY. Techniques for primary culture of human breast cancer cells and measurement of their prostaglandin secretion. Clin Sci. 1992;83:347–52.PubMed Watson J, Chuah SY. Techniques for primary culture of human breast cancer cells and measurement of their prostaglandin secretion. Clin Sci. 1992;83:347–52.PubMed
13.
Zurück zum Zitat Fulton AM, Zhang SZ, Chong YC. Role of the prostaglandin E2 receptor in mammary tumor metastasis. Cancer Res. 1991;51:2047–50.PubMed Fulton AM, Zhang SZ, Chong YC. Role of the prostaglandin E2 receptor in mammary tumor metastasis. Cancer Res. 1991;51:2047–50.PubMed
14.
Zurück zum Zitat Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–7.PubMed Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–7.PubMed
15.
Zurück zum Zitat Rosai J. Rosai and Ackerman’s surgical pathology. In: Rosai J, editor. Breast. Philadelphia: Mosby Year Book; 2004. p. 1763–876. Rosai J. Rosai and Ackerman’s surgical pathology. In: Rosai J, editor. Breast. Philadelphia: Mosby Year Book; 2004. p. 1763–876.
16.
Zurück zum Zitat Leo C, Faber S, Hentschel B, Höckel M, Horn LC. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol. 2006;10:327–32.PubMedCrossRef Leo C, Faber S, Hentschel B, Höckel M, Horn LC. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol. 2006;10:327–32.PubMedCrossRef
17.
Zurück zum Zitat Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Wael T, Einman G. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer. 2006;43:163–8.PubMedCrossRef Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Wael T, Einman G. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer. 2006;43:163–8.PubMedCrossRef
18.
Zurück zum Zitat Cho MH, Yoon JH, Jaegal YJ, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast. 2006;15:390–8.PubMedCrossRef Cho MH, Yoon JH, Jaegal YJ, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast. 2006;15:390–8.PubMedCrossRef
19.
Zurück zum Zitat Oliviera VM, Piato S, Silva ALG. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat. 2006;95:235–41.CrossRef Oliviera VM, Piato S, Silva ALG. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat. 2006;95:235–41.CrossRef
20.
Zurück zum Zitat Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoiera I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429–34.PubMedCrossRef Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoiera I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429–34.PubMedCrossRef
21.
Zurück zum Zitat Ristimaki A, Sivula A, Lundin M, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632–5.PubMed Ristimaki A, Sivula A, Lundin M, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632–5.PubMed
22.
Zurück zum Zitat Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C. COX-2 expression in invasive breast cancer correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol. 2007;15:255–9.PubMedCrossRef Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C. COX-2 expression in invasive breast cancer correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol. 2007;15:255–9.PubMedCrossRef
23.
Zurück zum Zitat Bundred NJ, Barnes NLP. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer. 2005;93:S10–5.PubMedCrossRef Bundred NJ, Barnes NLP. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer. 2005;93:S10–5.PubMedCrossRef
24.
Zurück zum Zitat Witton CJ, Hawe SJK, Cooke TJ, Bartlett JM. Cyclooxygenase.2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004;45:47–54.PubMedCrossRef Witton CJ, Hawe SJK, Cooke TJ, Bartlett JM. Cyclooxygenase.2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004;45:47–54.PubMedCrossRef
25.
Zurück zum Zitat Robertson FM, Mallery SR, Bergdall-Costell VK, et al. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. 2007;27:719–27.PubMed Robertson FM, Mallery SR, Bergdall-Costell VK, et al. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. 2007;27:719–27.PubMed
26.
Zurück zum Zitat Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer. 2004;91:359–65.PubMed Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer. 2004;91:359–65.PubMed
27.
Zurück zum Zitat Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001;8:97–114.PubMedCrossRef Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001;8:97–114.PubMedCrossRef
28.
Zurück zum Zitat Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004;90:423–9.PubMedCrossRef Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004;90:423–9.PubMedCrossRef
Metadaten
Titel
The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast
verfasst von
Nagehan Ozdemir Barısık
Sevinc Hallac Keser
Aylin Ege Gul
Sibel Sensu
Nilufer Onak Kandemir
Hasan Fehmi Kucuk
Mahmut Gumus
Nimet Karadayı
Publikationsdatum
01.09.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9503-6

Weitere Artikel der Ausgabe 3/2011

Medical Oncology 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.